FMP
Oct 30, 2025
Baxter International Inc. (NYSE:BAX) is a global healthcare company that provides a broad portfolio of essential medical products, including devices, pharmaceuticals, and biotechnology. The company operates in various segments, with a focus on Medical Products and Therapies. BAX faces competition from other healthcare giants like Johnson & Johnson and Medtronic.
On October 30, 2025, Stifel Nicolaus set a price target of $22 for BAX, while the stock was priced at $19.18. This target suggests a potential upside of approximately 14.73%. Despite this optimistic outlook, BAX has faced challenges, including a significant drop in its stock price, reaching a 52-week low.
Baxter's recent financial performance shows mixed results. The company reported a third-quarter adjusted EPS of 69 cents, surpassing both management's guidance of 58-62 cents and Wall Street's estimate of 60 cents. However, the company's decision to lower its 2025 guidance has impacted investor sentiment.
Baxter's sales for the third quarter were $2.84 billion, a 5% increase year-over-year on a reported basis and a 2% increase on an operational basis. This closely aligns with the consensus of $2.88 billion. However, the management had anticipated higher growth, which may have contributed to the stock's decline.
The Medical Products and Therapies segment reported sales of approximately $1.33 billion, a 1% decline on both a reported and operational basis. This decline was mainly due to reduced sales in the Infusion Therapies and Technologies division, although strong global demand for other products partially offset this.
Introduction In corporate finance, assessing how effectively a company utilizes its capital is crucial. Two key metri...
Bank of America analysts reiterated a bullish outlook on data center and artificial intelligence capital expenditures fo...
Pinduoduo Inc., listed on the NASDAQ as PDD, is a prominent e-commerce platform in China, also operating internationally...